Меню
Идёт набор NCT02560883

Hairy Cell Leukemia Patient Data Registry

Наблюдательное Leukemia, Other

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Leukemia, Other. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США, Австралия, Канада
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia

Обзор

The overall objective is to develop a clinical data registry that can be used to facilitate research with the ultimate goal of reducing the morbidity and/or mortality and improving the quality of life of patients diagnosed or living with hairy cell leukemia. With approximately 1,000 new cases of this rare disease identified in the US each year, HCL represents 2% of all cases of leukemia in adults. Considering the rarity of this chronic leukemia, the Hairy Cell Leukemia Foundation (HCLF), in partnership with investigators from its Centers of Excellence, seeks to develop a registry to help researchers identify new trends in outcomes, recognize the most effective treatments, discover previously unknown complications of the disease, and design clinical trials for new therapies.

Подробное описание

This clinical registry is being established to collect de-identified information on this rare disease. The registry created by assimilation of de- identified coded patient data will centralize information that can be used to improve the management of the many complications of this disease and its treatment. This study is focused on collection of clinically and biologically meaningful endpoints across multiple institutions; as such, it is not focused on a specific set of hypotheses but will collect data that will facilitate such analyses. The investigators will collect information related to the symptoms and the clinical course of the disease, to the complications from the disease and its treatment, presence of minimal residual disease, frequency of relapse and subsequent management, data on novel molecular markers associated with the prognosis.

In conjunction with the Department of Bioinformatics at The Ohio State University, the investigators have created a system for safeguarding the confidentiality and the identity of all patients who agree to participate in this research registry. Each participating institution will be responsible for de-identification of the data, using software developed by The Ohio State University, Department of Biomedical Informatics, before it is used in the registry. Each institution will confidentially maintain a code for linking this information to an individual patient.

Each participating institution will have direct control over the data contained in the registry that is associated with their respective patient population. As a result of these measures, should a patient wish to withdraw from the registry, the responsible institution will be able to immediately remove all records related to that patient from the registry.

Первичные конечные точки

  • Surveillance [Срок оценки: up to 25 years]
Вторичные конечные точки (1)
  • Research [Срок оценки: up to 25 years]

Критерии участия

Inclusion:

  • Patients with classic hairy cell leukemia
  • Patients with the variant of hairy cell leukemia.

Exclusion:

  • Children are excluded from the study, since Hairy Cell Leukemia wasn't described in children.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

США · 5 центров
  • University of Miami/Soffer Clinical Research Center — Miami
  • Mount Sinai Medical Center of Florida — Miami Beach
  • Mayo Clinic — Rochester
  • University of Rochester /Wilmot Cancer Institute — Rochester
  • Ohio State University Comprehensive Cancer Center — Columbus
Канада · 2 центра
  • BC Cancer, Part of the Provincial Health Services Authority — Vancouver
  • Cancer Care Manitoba — Winnipeg
Австралия · 1 центр
  • Peter MacCallum Cancer Center — Melbourne

Идентификаторы

NCT: NCT02560883 · OSU-12194

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗